Open-Label Placebo Effects on Social Anxiety

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00036107

Enrollment

Registered

2025-02-07

Start date

2025-03-10

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subclinical social anxiety

Interventions

Group 1: OLP group (Open-Label Placebo): OLP intake prior to the second short talk Group 2: Control group: No OLP intervention prior to the second short talk

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: SIAS-total score >= 20 SPS-total score >= 15

Exclusion criteria

Exclusion criteria: Self-reported mental or neurological disorders (except for social anxiety); clinical manifestation of social anxiety (SIAS total score >36, SPS total score >26); currently ongoing psychotherapy; use of psychotropic medication.

Design outcomes

Primary

Measure	Time frame
Comparison of the two groups regarding self-reported anxiety and avoidance pressure (Likert scale from "not at all" to "very"), heart rate, and behavioral observation (indicators of social anxiety; rating scales from "not at all" to "very").	—

Secondary

Measure	Time frame
Expected and perceived efficacy as well as the plausibility of the OLP intervention (Likert scale from "not at all" to "very"), correlations between the OLP effect and sociotropy (measured via the Sociotropy-Autonomy Scale, SAS).	—

Countries

Austria

Contacts

Public ContactWolfgang Kogler

Universität Graz

wolfgang.kogler@uni-graz.at+43 (0)316 380 - 8514

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026